A5035622739- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Immune cells in cancer
- Polyomavirus and related diseases
- Retinoids in leukemia and cellular processes
- Eosinophilic Disorders and Syndromes
- Childhood Cancer Survivors' Quality of Life
- Sarcoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Cutaneous lymphoproliferative disorders research
- COVID-19 and healthcare impacts
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- COVID-19 Clinical Research Studies
- Mycobacterium research and diagnosis
- Renal Transplantation Outcomes and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
King Fahd Medical City
2019-2024
King Faisal Specialist Hospital & Research Centre
2022-2024
The University of Texas MD Anderson Cancer Center
2018-2024
Alfaisal University
2022
Leukemia Research Foundation
2019
St. Elizabeth's Medical Center
2011-2013
Tufts University
2011-2013
Abstract Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this single-arm trial, in which patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) were treated azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously nivolumab 3 mg/kg on 14, every 4 6 weeks. For the seventy who treated, median age was 70 years (range, 22–90) number of prior therapies...
The majority of studies that provide insights into the influence microbiome on health hematologic malignancy patients have concentrated transplant setting. Here, we sought to assess predictive capacity gastrointestinal and its relationship infectious outcomes in with acute myeloid leukemia (AML).
Abstract Background The revised 2017 European LeukemiaNet (ELN) classification (ELN‐2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms‐like tyrosine kinase ( FLT3 )–internal tandem duplication (ITD) allele ratio (AR) considered for stratification. To best authors' knowledge, usefulness ELN‐2017 in comparison ELN‐2010 younger AML has not been validated to date. Methods authors performed a retrospective study on...
Key Points IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with IDH1/2-mutated post–MPN AML. Complete remission was achieved 3/7 (1 attaining MRD–) new AML treated IDH1/2-i combinations.
Background There have been concerns regarding increased peritransplantation complications, especially severe acute graft‐versus‐host disease (aGVHD), in patients with prior use of checkpoint inhibitors (CPI) before hematopoietic stem cell transplantation (HSCT). Methods The authors performed a retrospective study 43 myeloid leukemia and/or myelodysplastic syndromes who were treated an antiprogrammed death protein 1 (PD‐1) (32 patients) or anticytotoxic T‐lymphocyte–associated 4 (CTLA‐4) (9...
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, male-predominant hematologic malignancy with poor outcomes and just one recently approved agent (tagraxofusp). It characterized by the abnormal proliferation of precursor cells (pDCs) morphologic molecular similarities to acute myeloid leukemia (AML) myelodysplastic syndrome (MDS)/chronic myelomonocytic (CMML) in its presentation within bone marrow peripheral blood. To identify disease-specific features BPDCN, we...
Acute myeloid leukemia (AML) remains a difficult disease to treat disease. In phase 2 clinical trial in patients with relapsed/refractory AML, combining the hypomethylating agent, azacitidine, PD-1 checkpoint inhibitor, nivolumab, demonstrated encouraging response rates (33%), median event-free, and overall survival, compared historical cohort of contemporary treated azacitidine-based therapies, an acceptable safety profile. Biomarkers are yet be determined. this study, we leveraged...
Abstract: Fms-related-tyrosine kinase 3 ( FLT3 ) mutations occur in approximately a third of acute myeloid leukemia (AML) patients and confer an adverse prognosis. Numerous studies have evaluated targeting as single agent combination approaches frontline relapsed AML. At this time, midostaurin, multikinase inhibitor, is the only FLT3-inhibitor that US FDA approved to be used with induction therapy FLT3- mutated AML setting based on improved overall survival noted RATIFY Phase III trial. The...
Azacitidine, a hypomethylating agent, has caused paradigm shift in the outcomes of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not eligible for stem cell transplantation, particularly combination BCL2 IDH inhibitors. Azacitidine Azacitidine-based combinations have been widely considered safe low-intensity therapy when compared to traditional conventional treatments. The development lung toxicity from azacitidine is well-characterized adverse event....
Acute myeloid leukemia (AML) is a heterogeneous malignancy of the blood primarily treated with intensive chemotherapy. The allogeneic T-cell antileukemic activity via donor lymphocyte infusions and stem cell transplantation suggests potential role for checkpoint blockade therapy in AML. While clinical trials employing these treatments have fallen short expected results, deeper exploration into functional states T cells AML could bridge this knowledge gap. In study, we analyzed polyfunctional...
Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45-55% in patients with relapsed/refractory (R/R) FLT3-mutated AML phase II/III trials. However, > 85% treated were prior FLT3i naïve. The response to sequential exposure remain poorly defined. We retrospectively reviewed between November 2006 and December 2019. In frontline a (cohort 1), the CRc median overall survival (OS) first (n = 56), second 32), third FLT3i-based 8) therapy 77%, 31%, 25%,...
Background Immune checkpoint inhibitors (ICI), combined with hypomethylating agents, can be used to treat acute myeloid leukemia (AML), but this strategy results in a high rate of pneumonitis. The authors sought determine risk factors for pneumonitis development and whether increased mortality. Methods conducted retrospective review 258 AML patients who received ICI‐containing regimens from 2016 2018. A multidisciplinary adjudication committee diagnosed pneumonia by reviewing symptoms,...